In a recent study published in Drug Testing and Analysis (DOI: 10.1002/dta.2378), authored by Heather K. Knych et al, UCT’s Clean Screen® DAU was employed to extract grapiprant following oral administration to exercised thoroughbred horses. Grapiprant is a newly approved non‐ cyclooxygenase inhibiting non‐steroidal anti‐inflammatory drug that has demonstrated efficacy and safety in other species. As long‐term use of these drugs can adversely impact the health of the horse, anti‐inflammatories with a more favorable safety profile are warranted.
The objectives of the current study were to describe drug concentrations and the pharmacokinetics of grapiprant in exercised Thoroughbred horses and to develop an analytical method that could be used to regulate its use. Grapiprant, at a dose of 2 mg per kg was administered orally to 12 horses. Blood and urine samples were collected prior to and for up to 96 hours post drug administration.
It was observed that grapiprant remained above the limit of quantification (LOQ) of the assay (0.005 ng per mL) in serum for 72 hours post administration and urine concentrations were above the LOQ until 96 hours. The Cmax, Tmax and elimination half‐life were 31.9 ± 13.9 ng per mL, 1.5 ± 0.5 hours and 5.86 ± 2.46 hours, respectively. The drug was well tolerated in all horses at a dose of 2 mg per kg. Results support further study of this compound in horses. Furthermore, development of a highly sensitive analytical method using SPE extraction demonstrate that this compound can be adequately regulated in performance horses
This study that equine toxicologists routinely use UCT’s DAU sorbent when studying the newest pharmaceutical medications. For more information regarding Clean Screen® SPE sorbents, applications and methods please click here.